Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIK066 in overweight/obese women with PCOS
NCT03152591Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in polycystic ovary syndrome (PCOS) comparing LIK066 with Placebo (2 arms). Primary endpoint: Change in Average Morning Fasting Free Testosterone Blood Concentrations From Baseline at Day 15. Started Jul 2017; status: completed.
02
Drugs
licogliflozin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT03152591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03152591.